Southeast Regional Radiation Medical Center and Selbion Join Forces for New Radiopharmaceutical Drug Development

"Transforming Busan into a Hub for Advanced Radiation Medical Science"

The Southeast Regional Radiation Medical Center (Director: Lee Changhoon) is partnering with Selbion Co., Ltd. to embark on the development of new radiopharmaceutical drugs.

The medical center announced on the 10th that it had signed a business agreement with Selbion on November 7 at the center's Welfare Center, aiming to cooperate in the fields of radiopharmaceuticals and targeted radioligand therapy.

Through this agreement, the two organizations will collaborate in various areas, including joint research and clinical trials on radiopharmaceuticals and targeted therapies, shared use of research infrastructure and equipment, joint planning and participation in research projects, and revitalization of the Southeast Radiation Medical and Science Industrial Complex.

The medical center plans to strengthen its capabilities across the entire process from research and development to clinical application, based on its radiopharmaceutical GMP (Good Manufacturing Practice) facility, which began operations last year. Selbion aims to establish a production base for radiopharmaceuticals in Busan and the Southeast region, and to enhance its competitiveness in new drug development by utilizing the joint research and development infrastructure.

Lee Changhoon, Director of the medical center, stated, "Radiopharmaceuticals are attracting global attention as next-generation innovative cancer treatment technologies. If research and development companies gather in Busan's Southeast Radiation Medical and Science Complex, we can achieve rapid and efficient research outcomes." He added, "By cooperating with the Ministry of Science and ICT, Busan Metropolitan City, and Gijang County, we will accelerate the creation of an advanced radiation medical science complex and turn this agreement into tangible commercialization results."

Kim Kwon, CEO of Selbion, emphasized, "Radiopharmaceuticals are being recognized as next-generation technology overseas as well. Korea can also be competitive if we have regulatory easing, experienced researchers, and clinical hospital infrastructure." He added, "By combining the medical center's GMP facilities, skilled researchers, and the infrastructure of the Southeast Radiation Complex, it will be possible to realize commercialization from basic research in the shortest possible time."

Founded in 2010, Selbion is a biotech company specializing in the development of radiopharmaceutical therapeutics and diagnostics. It operates research institutes at the Seoul National University Cancer Research Institute, the Korea Institute of Radiological & Medical Sciences, and Bundang Seoul National University Hospital. With this agreement, Selbion also plans to accelerate its expansion into overseas markets such as Japan and China.

The Southeast Regional Radiation Medical Center is taking a commemorative photo after signing a business agreement with Selbion for the development of new radiopharmaceutical drugs.

This content was produced with the assistance of AI translation services.